[go: up one dir, main page]

KR987000303A - 신규한 퀴누클리딘 유도체 및 이의 의약 조성물(Novel quinuclidine derivatives and medicinal composition thereof) - Google Patents

신규한 퀴누클리딘 유도체 및 이의 의약 조성물(Novel quinuclidine derivatives and medicinal composition thereof) Download PDF

Info

Publication number
KR987000303A
KR987000303A KR1019970703649A KR19970703649A KR987000303A KR 987000303 A KR987000303 A KR 987000303A KR 1019970703649 A KR1019970703649 A KR 1019970703649A KR 19970703649 A KR19970703649 A KR 19970703649A KR 987000303 A KR987000303 A KR 987000303A
Authority
KR
South Korea
Prior art keywords
group
groups
mono
atom
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970703649A
Other languages
English (en)
Other versions
KR100386487B1 (ko
Inventor
마코토 다케우치
료 나이토
마사히코 하야카와
요시노리 오카모토
야스히로 요네토쿠
겐 이케다
야스오 이소무라
Original Assignee
오노다 마사요시
야마노우치세이야쿠가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR987000303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오노다 마사요시, 야마노우치세이야쿠가부시키가이샤 filed Critical 오노다 마사요시
Publication of KR987000303A publication Critical patent/KR987000303A/ko
Application granted granted Critical
Publication of KR100386487B1 publication Critical patent/KR100386487B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Tea And Coffee (AREA)

Abstract

화학식 I의 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염과 이를 함유하는 의약 조성물.
화학식 I
상기 화학식 I에서, A환은 아릴기, 사이클로알킬기, 사이클로알케닐기, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1 내지 4개 함유하는 헤테로아릴기 또는 5 내지 7원 포화 헤테로 환 기이며, 이들 환은 임의의 치환기로 치환 될 수 있으며, X는 단일 결합 또는 메틸렌기이며, R은 할로겐 원자, 수산기, 저급 알콕시기, 카복실기, 저급 알콕시카보닐기, 저급 아실기, 머캅토기, 저급 알킬티오기, 설포닐기, 저급 알킬설포닐기, 설피닐기, 저급 알킬설피닐기, 설폰아미드기, 저급 알칸설폰아미드기, 카바모일기, 티오카바모일기, 모노-또는 디-저급 알킬카바모일기, 니트로기, 시아노기, 아미노기, 모노-또는 디-저급 알킬아미노기, 메틸렌디옥시기 또는 에틸렌디옥시기이거나, 할로겐 원자, 수신기, 저급 알콕시기, 아미노기 또는 모노-또는 디-저급 알킬아미노로 치환될 수 있는 저급 알킬기이며, 1은 0 또는 1이며, m은 0 또는 1 내지 3의 정수이며, n은 1 또는 2의 정수이다, 화합물은 무스카린 M3수용체에 대한 길항 효과를 가지고 비뇨기 질환, 호흡기 질환 또는 소화기 질환의 예방 및 치료제로서 유용하다.

Description

신규한 퀴누클리딘 유도체 및 이의 의약 조성물(Novel quinuclidine derivatives and medicinal composition thereof).
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 화학식 I의 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
    화학식 I
    상기 화학식 I에서, A환은 아릴기, 사이클로알킬기, 사이클로알케닐기, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1내지 4개 함유하는 헤테로아릴기 또는 5내지 7원 포화 헤테로 환 기이며, 이들 환은 임의의 치환기로 치환될 수 있으며, X는 단일 결합 또는 메틸렌기이며, R은 할로겐 원자, 수산기, 저급 알콕시기, 카복실기, 저급 알콕시카보닐기, 저급 아실기, 머캅토기, 저급 알킬티오기, 설포닐기, 저급 알킬설포닐기, 설피닐기, 저급 알킬설피닐기, 설폰아미드기, 저급 알칸설폰아미드기, 카바모일기, 티오카바모일기, 모노-또는 디-저급 알킬카바모일기, 니트로기, 시아노기, 아미노기, 모노-또는 디-저급 알킬아미노기, 멜틸렌디옥시기 또는 에틸렌디옥시기이거나, 할로겐 원자, 수산기, 저급 알콕시기, 아미노기 또는 모노- 또는 디-저급 알킬아미노로 치환될 수 있는 저급 알킬기이며, 1은 0 또는 1이며, m은 0또는 1 내지 3의 정수이며, n은 1 또는 2의 정수이다.
  2. 제1항에 있어서, A환이 아릴기, 사이클로알킬기, 사이클로알케닐기, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1 내지 4개 함유하는 헤테로아릴기 또는 5원 내지 7원 포화 헤테로 환 기 이며, 이들 환은 할로겐 원자, 수산기, 저급 알콕시기, 카복실기, 저급 알콕시카보닐기, 저급 아실기, 머캅토기, 저급 알킬티오기, 설포닐기, 저급 알킬설포닐기, 설피닐기, 저급 알킬설피날기, 설폰아미드기, 저급 알칸설폰아미드기, 카바모일기, 티오카바모일기, 모노- 또는 디-저급 알킬카바모일기, 니트로기, 시아노기, 아미노기, 모노-또는 디-저급 알킬아미노기, 메틸렌디옥시기 또는 에틸렌디옥시기이거나, 할로겐 원자, 수산기, 저급 알콕시기, 아미노기 또는 모노-또는 디-저급 알킬아미노기로 치환될 수 있는 저급 알킬기로 이루어진 치환기로 치환될 수 있는 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  3. 제2항에 있어서, R이 할로겐 원자, 저급 알킬기, 수산기, 저급 알콕시기, 니트로기, 시아노기, 아미노기 또는 모노- 또는 디-저급 알킬아미노기이며, A환이 아릴기, 사이클로알킬기, 사이클로알케닐기, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1내지 4개 함유하는 5원 또는 6원의 단환 헤테로아릴기 또는 5원 내지 7원 포화 헤테로 환 기이며, 이들 환은 할로겐 원자, 저급 알킬기, 수산기, 저급 알콕시기, 니트로기, 시아노기, 아미노기, 또는 모노- 또는 디-저급 알킬아미노기로 치환될 수 있는 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  4. 제3항에 있어서, m이 0이며 A환이 할로겐 원자, 저급 알킬기, 수산기 또는 저급 알콕시기로 치환될 수 있는 아릴기, 사이클로알킬기 또는 사이클로알케닐기이거나, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1내지 4개 함유하는 5원 또는 6원의 단환 헤테로아릴기인 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  5. 제4항에 있어서, A환이 할로겐 원자 또는 저급 알킬기로 치환될 수 있는 페닐기, 사이클로알킬기, 피릴딜기, 푸릴기 또는 티에닐기인 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  6. 제2항 내지 제5항 중의 어느 한 항에 있어서, X가 단일 결합인 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  7. 제2항 내지 제6항 중의 어느 한 항에 있어서, n이 2인 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  8. 제1항에 있어서, 3-퀴누클리디닐 1-페닐-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1-(4-피리딜)-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1, 2, 3, 4-테트라하이드로-1-(2-티에닐) -2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1, 2, 3, 4-테트라하이드로-1-(3-티에닐)-2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1-(2-푸릴)-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린 카복실레이트, 3-퀴누클리디닐 1-(4-클로로페닐)-1, 2, 3, 4-테트라히아드로-2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1-(4-플루오로페닐)-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린카복실레이트, 3-퀴누블리디닐 1, 2, 3, 4-데트라하이드로-1-(4-톨릴)-2-이소퀴놀린카복시레이트, 3-퀴누클리디닐 1-사이클로헥실-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린카복실레이트, 3-퀴누클리디닐 1-(3-푸릴)-1, 2, 3, 4-테트라하이드로-2-이소퀴놀린카복실레이트 및 이들의 광학활성체로 이루어진 그룹으로부터 선택된 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염.
  9. 화학식 I의 퀴누클리딘 유도체, 이의 염, 이의 N-옥사이드 또는 이의 4급 암모늄염과 약제학적으로 허용되는 담체를 함유하는 의약 조성물.
    화학식 I
    상기 화학식 I에서, A환은 아릴기, 사이클로알킬기, 사이클로알케닐기, 산소원자, 질소원자 및 황원자로 이루어진 헤테로 원자를 1내지 4개 함유하는 헤테로아릴기 또는 5 내지 7원 포화 헤테로 환 기이며 이들 환은 임의 치환기로 치환될 수 있으며, X는 단일 결합 또는 메틸렌기이며, R은 할로겐 원자, 수산기, 저급 알콕시기, 카복실기, 저급 알콕시카보닐기, 저급 아실기, 머캅토기, 저급 알킬티오기, 설포닐기, 저급 알킬설포닐기, 설피닐기, 저급 알킬설피닐기, 설폰아미드기, 저급 알칸설폰아미드기, 카바모일기, 티오카바모일기, 모노- 또는 디-저급 알킬카바모일기, 니트로기, 시아노기, 아미노기, 모노-또는 디-저급 알킬아미노기, 메틸렌디옥시기 또는 에틸렌디옥시기이거나, 할로겐 원자, 수산기, 저급 알콕시기, 아미노기 또는 모노- 또는 디-저급 알킬아미노기로 치환될 수 있는 저급 알킬기이며, 1은 0 또는 1이며, m은 0또는 1 내지 3의 정수이며, n은 1 또는 2의 정수이다.
  10. 제9항에 있어서, 무스카린 M3수용체 길항제인 의약 조성물.
  11. 제10항에 있어서, 무스카린 M3수용체 길항제가 비뇨기 질환(신경성 빈뇨, 신경 원인성 방광, 야뇨증, 불안정 방광, 방광 경축 및 만성 방광염에서의 요실금과 빈뇨) 또는 호흡기 질환(만성 폐색성 폐질환, 만성 기관지염, 천식 및 비염)의 예방 및 치료제인 의약 조성물.
KR1019970703649A 1994-12-28 1995-12-27 신규한퀴누클리딘유도체및이의약제학적조성물 Expired - Lifetime KR100386487B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP94-327045 1994-12-28
JP32704594 1994-12-28

Publications (2)

Publication Number Publication Date
KR987000303A true KR987000303A (ko) 1998-03-30
KR100386487B1 KR100386487B1 (ko) 2003-09-26

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703649A Expired - Lifetime KR100386487B1 (ko) 1994-12-28 1995-12-27 신규한퀴누클리딘유도체및이의약제학적조성물

Country Status (24)

Country Link
US (2) US6017927A (ko)
EP (1) EP0801067B1 (ko)
JP (1) JP3014457B2 (ko)
KR (1) KR100386487B1 (ko)
CN (1) CN1045601C (ko)
AT (1) ATE233761T1 (ko)
AU (1) AU695616B2 (ko)
CA (1) CA2208839C (ko)
DE (2) DE69529844T2 (ko)
DK (1) DK0801067T3 (ko)
ES (1) ES2193208T3 (ko)
FI (1) FI115631B (ko)
FR (1) FR04C0032I2 (ko)
HU (1) HU223778B1 (ko)
LU (1) LU91133I9 (ko)
MX (1) MX9704880A (ko)
NL (1) NL300141I1 (ko)
NO (4) NO2005012I1 (ko)
NZ (1) NZ298144A (ko)
PL (1) PL182344B1 (ko)
PT (1) PT801067E (ko)
RU (1) RU2143432C1 (ko)
TW (1) TW305842B (ko)
WO (1) WO1996020194A1 (ko)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
ATE305468T1 (de) * 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
US7335668B2 (en) * 2001-07-10 2008-02-26 Astellas Pharma Inc. Pharmaceutical composition for therapy of interstitial cystitis
PL211250B1 (pl) 2001-12-20 2012-04-30 Chiesi Farma Spa Pochodne karbaminianu 1-alkilo-1-azoniabicyklo [2.2.2] oktanu, jej zastosowania, kompozycja farmaceutyczna zawierająca ten związek oraz związek pośredni
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
HK1079787A1 (zh) 2002-07-31 2006-04-13 Ranbaxy Laboratories Limited 用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
WO2004014363A1 (en) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
AU2003269380A1 (en) * 2002-10-29 2004-05-25 Pharmacia & Upjohn Company Llc Quinuclidinium derivatives as antimuscarinic agents
WO2004052857A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
MXPA05006656A (es) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100406009C (zh) 2003-04-10 2008-07-30 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物
AU2003223010A1 (en) 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1626957A1 (en) 2003-04-11 2006-02-22 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005075474A1 (ja) * 2004-02-09 2005-08-18 Astellas Pharma Inc. コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
EP1726304A4 (en) * 2004-03-16 2010-04-28 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACIN
BRPI0509062A (pt) * 2004-03-25 2007-08-21 Astellas Pharma Inc composição para preparação farmacêutica sólida de solifenacina ou seu sal
CN101601673B (zh) * 2004-03-25 2012-07-18 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
RU2418797C2 (ru) * 2004-12-22 2011-05-20 Мемори Фармасьютиклз Корпорейшн Лиганды никотинового рецептора альфа-7, их получение и применение
MX2007007911A (es) * 2004-12-27 2007-08-20 Astellas Pharma Inc Composicion farmaceutica granular estable de solifenacina o su sal.
AU2005320672B2 (en) * 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1904495A2 (en) * 2005-07-11 2008-04-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007076116A2 (en) * 2005-12-21 2007-07-05 Teva Pharmaceutical Industries Ltd. Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2046751A4 (en) * 2006-07-19 2010-12-29 Reddys Lab Ltd Dr PROCESS FOR PRODUCING SOLIFENACIN AND ITS SALTS
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US20080114028A1 (en) * 2006-07-24 2008-05-15 Tamas Koltai Process for preparing polymorphic forms of solifenacin succinate
WO2008019103A2 (en) * 2006-08-03 2008-02-14 Teva Pharmaceutical Industries Ltd Solifenacin base forms and preparation thereof
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2102200A2 (en) * 2006-11-22 2009-09-23 Medichem, S.A. An improved process for the synthesis of solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
EP2142540A2 (en) * 2007-03-30 2010-01-13 Medichem S.A. An improved process for the synthesis of solifenacin
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
WO2009011844A1 (en) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Processes for solifenacin preparation
CA2697137A1 (en) 2007-07-20 2009-01-29 Astellas Pharma Inc. Pharmaceutical composition for amelioration of lower urinary tract symptoms associated with prostatomegaly
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
EP2216021B1 (en) 2007-11-02 2012-10-17 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
EP2484681A1 (en) 2007-12-04 2012-08-08 Cadila Healthcare Limited Chemically and chirally pure gentisate salt of solifenacin
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2718411C (en) 2008-03-27 2016-02-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
EP3067353B1 (en) 2008-07-29 2017-11-22 KRKA, D.D., Novo Mesto A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
ES2603747T3 (es) 2009-02-04 2017-03-01 Astellas Pharma Inc. Composición farmacéutica para administración oral
WO2010103529A1 (en) 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof
WO2010113840A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
EP2554184B1 (en) 2010-03-31 2016-10-26 ONO Pharmaceutical Co., Ltd. Preventive and/or remedy for hand and foot syndrome
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
HUE029400T2 (en) 2010-05-19 2017-03-28 Astellas Pharma Inc Pharmaceutical composition containing Solifenacin
US8772491B2 (en) 2010-06-28 2014-07-08 Aurobindo Pharma Ltd Process for the preparation of solifenacin succinate
ES2596293T3 (es) 2010-07-05 2017-01-05 Crystal Pharma S.A.U Sales de solifenacina
WO2012062916A1 (de) 2010-11-11 2012-05-18 Hexal Ag Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012154774A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
WO2012175119A1 (en) 2011-06-22 2012-12-27 Isochem Process for the preparation of solifenacin and salts thereof
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (en) 2012-07-02 2014-01-09 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
EP3023424B1 (en) * 2013-07-13 2019-02-27 Beijing Shuobai Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
CA2944714C (en) 2014-05-06 2023-05-16 Anthony G. Visco Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
EP3724188B1 (en) 2017-12-12 2023-06-07 Arkuda Therapeutics Progranulin modulators and methods of using the same
CA3099655A1 (en) 2018-05-08 2019-11-14 Nippon Shinyaku Co., Ltd. Azabenzimidazole compounds and pharmaceutical
JP2022545314A (ja) 2019-06-12 2022-10-27 アルクダ セラピューティクス プログラニュリンモジュレーターおよびその使用方法
KR20220100627A (ko) 2019-11-13 2022-07-15 니뽄 신야쿠 가부시키가이샤 아자벤즈이미다졸 화합물 및 의약
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
EP1424021B1 (en) * 2002-11-27 2006-09-13 Selmac S.r.l. Device for positioning and clamping shaped elements and machine equipped with this device

Also Published As

Publication number Publication date
NO973027L (no) 1997-08-28
NL300141I2 (nl) 2004-04-01
ATE233761T1 (de) 2003-03-15
PL321019A1 (en) 1997-11-24
EP0801067A4 (en) 1998-03-11
AU695616B2 (en) 1998-08-20
NO2017055I1 (no) 2017-11-06
HUT77006A (hu) 1998-03-02
DE69529844T2 (de) 2004-03-04
MX9704880A (es) 1997-10-31
JP3014457B2 (ja) 2000-02-28
ES2193208T3 (es) 2003-11-01
CN1171109A (zh) 1998-01-21
NL300141I1 (nl) 2004-04-01
NO2005016I1 (no) 2005-08-29
NO2005012I1 (no) 2005-06-06
NO2017055I2 (no) 2017-11-06
NO2005016I2 (no) 2008-02-11
TW305842B (ko) 1997-05-21
US6174896B1 (en) 2001-01-16
LU91133I9 (en) 2018-08-01
FR04C0032I2 (fr) 2005-10-21
CN1045601C (zh) 1999-10-13
NO973027D0 (no) 1997-06-27
PT801067E (pt) 2003-07-31
CA2208839C (en) 2006-01-31
JPH09508401A (ja) 1997-08-26
FI972775A7 (fi) 1997-08-22
KR100386487B1 (ko) 2003-09-26
HU223778B1 (hu) 2005-01-28
DE122004000048I2 (de) 2006-02-02
WO1996020194A1 (en) 1996-07-04
EP0801067B1 (en) 2003-03-05
RU2143432C1 (ru) 1999-12-27
DK0801067T3 (da) 2003-06-30
PL182344B1 (pl) 2001-12-31
LU91133I2 (fr) 2005-03-29
CA2208839A1 (en) 1996-07-04
US6017927A (en) 2000-01-25
NO318026B1 (no) 2005-01-24
DE69529844D1 (de) 2003-04-10
FR04C0032I1 (ko) 2005-02-11
NZ298144A (en) 1998-04-27
AU4355396A (en) 1996-07-19
FI972775A0 (fi) 1997-06-27
FI115631B (fi) 2005-06-15
EP0801067A1 (en) 1997-10-15
DE122004000048I1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
KR987000303A (ko) 신규한 퀴누클리딘 유도체 및 이의 의약 조성물(Novel quinuclidine derivatives and medicinal composition thereof)
RU97112907A (ru) Новые производные хинуклидина и медицинские композиции, содержащие их
RU2470918C2 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β
JP2007513915A5 (ko)
RU2005120780A (ru) Соединения с конденсированным 1,3-дигидроимидазольным циклом
WO1996004254A3 (en) Benzodiazepine derivatives
KR970001327A (ko) 치환 피페리딘 유도체
RU2005109911A (ru) Соединения фенил-аза-бензимидазола для модуляции ige и подавления разрастания клеток
JP2002523502A5 (ko)
CO4990963A1 (es) Inhibidores del dominio sh2 de la familia src
US20150210717A1 (en) Specific inhibitors of protein p21 as therapeutic agents
JP2004501930A5 (ko)
DE122008000051I1 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
IE37538B1 (en) New 1,4-dihydropyridine carboxylic acid compounds their production and their medicinal use
RU96116128A (ru) Диазабициклические антагонисты нейрокинина
RU2006134020A (ru) Конденсированные производные пиразола
RU2003106397A (ru) Соединение 2-аминопиридина и его применение в медицине
EP1156045A4 (en) AMID DERIVATIVES AND DRUG COMPOSITIONS
KR880009928A (ko) N-헤테로시클릭-n(4-피페리딜) 아미드와 이러한 화합물들을 사용하는 방법 및 제약학적 조성물
EP1176141A4 (en) HETEROCYCLIC COMPOUNDS HAVING AN EFFECT ACTIVATING THE NICOTINE ACETYL CHOLINE -g (a) 4-g (b) 2-RECEPTOR
JP2007502275A5 (ko)
RU2003130752A (ru) Противозудные средства
RU2000104870A (ru) Производные фталазина и терапевтические средства для эректильной дисфункции
KR890005054A (ko) 치료제로서 유용한 4-아릴-5-카바모일-1, 4-디하이드로피리딘
KR930702345A (ko) 3,9-다아자비시클로(3,3,1) 노난-7-일 유도체, 이들의 제조를 위한 방법 및 중간체 및 이들을 함유한 제약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970531

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20001212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20021118

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20030226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20030523

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20030526

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20060511

Start annual number: 4

End annual number: 4

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20070413

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20030523

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20080710

Request date: 20070413

Appeal identifier: 2007105000035

PR1001 Payment of annual fee

Payment date: 20070511

Start annual number: 5

End annual number: 5

PG1701 Publication of correction

Publication date: 20080304

PR1001 Payment of annual fee

Payment date: 20080508

Start annual number: 6

End annual number: 6

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20070413

Effective date: 20080710

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20080710

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20070413

Decision date: 20080710

Appeal identifier: 2007105000035

PR1001 Payment of annual fee

Payment date: 20090508

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20100512

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20110421

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20120507

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20130503

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20130503

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20140502

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20140502

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20150416

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20150416

Start annual number: 13

End annual number: 13

PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20150715

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20030523

Comment text: Registration of Establishment

Decision date: 20160913

Request date: 20150715

Appeal identifier: 2015100003931

Appeal kind category: Confirmation of the scope of right_defensive

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20150729

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20030523

Comment text: Registration of Establishment

Decision date: 20150825

Request date: 20150729

Appeal identifier: 2015100004091

Appeal kind category: Confirmation of the scope of right_defensive

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20150825

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2015100004091

Request date: 20150729

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20150825

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20160303

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20030523

Comment text: Registration of Establishment

Decision date: 20161012

Request date: 20160303

Appeal identifier: 2016100000547

Appeal kind category: Confirmation of the scope of right_defensive

FPAY Annual fee payment

Payment date: 20160419

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20160419

Start annual number: 14

End annual number: 14

J301 Trial decision

Free format text: TRIAL NUMBER: 2015100003931; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150715

Effective date: 20160913

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20160913

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20150715

Decision date: 20160913

Appeal identifier: 2015100003931

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100000547; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160303

Effective date: 20161012

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20161012

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20160303

Decision date: 20161012

Appeal identifier: 2016100000547

PJ2001 Appeal

Patent event date: 20161012

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S02I

Patent event date: 20160913

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S02I

Patent event date: 20080710

Comment text: Trial Decision on Correction (Patent, Utility Model)

Patent event code: PJ20011S03I

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20170630

Appeal identifier: 2016200008636

Request date: 20161121

PJ2001 Appeal

Patent event date: 20161012

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S02I

Patent event date: 20160913

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S02I

Patent event date: 20080710

Comment text: Trial Decision on Correction (Patent, Utility Model)

Patent event code: PJ20011S03I

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20170630

Appeal identifier: 2016200009189

Request date: 20161209

FPAY Annual fee payment

Payment date: 20170420

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20170420

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term
PJ2002 Appeal before the supreme court

Request date: 20170717

Appeal identifier: 2017300001649

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20190117

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event date: 20161012

Patent event code: PJ20021S02I

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Patent event date: 20160913

Patent event code: PJ20021S02I

Comment text: Trial Decision on Correction (Patent, Utility Model)

Patent event date: 20080710

Patent event code: PJ20021S03I

Request date: 20170717

Appeal identifier: 2017300001632

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20190117

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016200008636; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161121

Effective date: 20170630

PJ1302 Judgment (patent court)

Request date: 20161209

Decision date: 20170630

Appeal identifier: 2016200009189

Appeal kind category: Confirmation of the scope of right_defensive

Patent event date: 20170828

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20161121

Decision date: 20170630

Appeal identifier: 2016200008636

Appeal kind category: Confirmation of the scope of right_defensive

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2017300001632; JUDGMENT (SUPREME COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170717

Effective date: 20190117

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20190211

Patent event code: PJ13031S01D

Decision date: 20190117

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20170717

Appeal identifier: 2017300001632